Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
5.37
+0.39 (7.83%)
At close: Apr 24, 2025, 4:00 PM
5.43
+0.06 (1.12%)
After-hours: Apr 24, 2025, 6:42 PM EDT
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2024. The number of employees decreased by 700 or -43.75% compared to the previous year.
Employees
900
Change (1Y)
-700
Growth (1Y)
-43.75%
Revenue / Employee
$1,159,556
Profits / Employee
-$211,778
Market Cap
291.79M
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
EBS News
- 2 days ago - Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 24 days ago - Emergent BioSolutions Announces Stock Repurchase Program - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - GlobeNewsWire
- 5 weeks ago - Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewsWire